Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

New Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

MediciNova’s Ibudilast Gains Brain Metastasis Validation Ahead of ALS Readout

By The Northwire Desk — AI Analysis Apr 27, 2026 · 19:00 4875
Executive Summary
  • Most Recent Release (April 27, 2026): MediciNova announced a peer-reviewed study published in Cancer Research demonstrating that its lead product MN-166 (ibudilast) blocks the MIF–CD74 signaling axis to suppress brain metastasis growth.
  • Key Findings: The study identifies tumor-derived MIF as a driver of pro-metastatic immune reprogramming in the brain and suggests secreted MIF could serve as a liquid biopsy biomarker.
  • Collaboration: MediciNova plans to collaborate with the Spanish National Cancer Research Centre (CNIO) on future clinical research targeting patients with solid tumors that have developed brain metastases.
  • Historical Context (2025-2026):
    • ALS Program (COMBAT-ALS): Enrollment of 234 patients completed in September 2025. Top-line results were initially targeted for year-end 2025 (Jan 6, 2026 message) but subsequently clarified to end of 2026 (Dec 8, 2025 & Jan 29, 2026 updates).
    • ALS Expanded Access: SEANOBI EAP enrolled 100 patients by January 2026 (50% of 200 target), funded by a $22 million NINDS grant.
    • CIPN Program (OXTOX): Enrollment completed December 2025 in Australia; data expected late 2026.
    • Metabolic Program (MN-001): Phase 2 enrollment completed November 2025; top-line data expected summer 2026. Mechanistic studies published regarding cholesterol efflux (Oct/Dec 2025).
Material Impact
  • Positive Validation: The publication in Cancer Research provides strong mechanistic support for MN-166 beyond its primary ALS indication, potentially expanding the Total Addressable Market (TAM) to include brain metastases from lung, breast, and melanoma.
  • Incremental Nature: This is preclinical/mechanistic data, not clinical efficacy data. It does not de-risk the binary outcome of the ongoing COMBAT-ALS Phase 2b/3 trial, which remains the primary value driver.
  • Timeline Discrepancy Risk: There is a notable inconsistency in management communication regarding the COMBAT-ALS top-line results. The January 6, 2026 CEO message targeted year-end 2025, while the December 8, 2025 enrollment update and January 29, 2026 EAP update both specify end of 2026. This suggests potential timeline slippage or optimistic forecasting in early-year communications.
  • Funding Stability: The reliance on a $22 million NIH grant for the SEANOBI program indicates that external funding is crucial to offset development costs, highlighting cash flow sensitivity.
4875 · Price
Company Overview
  • Company Profile: MediciNova is a biopharmaceutical company focused on the development of novel therapies for unmet medical needs, primarily in neurology and oncology.
  • Flagship Asset (MN-166/Ibudilast): A PDE4 inhibitor with anti-inflammatory properties. Currently in Phase 2b/3 for ALS (COMBAT-ALS), Phase 2 for Chemotherapy-induced Peripheral Neuropathy (CIPN), and exploring brain metastasis indications.
  • Secondary Asset (MN-001/Tipelukast): A leukotriene receptor antagonist/PDE inhibitor being developed for metabolic disorders including hypertriglyceridemia, NAFLD, and Type 2 Diabetes. Phase 2 enrollment completed as of late 2025.
  • Development Stage: Late-stage clinical development (Phase 2b/3) with multiple programs nearing data readouts in 2026.
Read the original news release →

More from

Jun 30, 2026 · 08:00

Clinical-stage biotech advances late-stage neurology and metabolic assets with H2 2026 data catalysts on track.

Other Jun 08, 2026 · 08:00

Late-stage biotech advancing MN-166 across neurology and oncology, with patent wins reinforcing IP moats while pivotal clinical data remains pending.

M&A / Property May 26, 2026 · 19:00

MediciNova Clears Trial Hurdle for MN-001; Q3 Data Release Looms Amidst ALS Pipeline Progress

Other Jan 29, 2026 · 18:00

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

Other Jan 06, 2026 · 09:00

2026 New Year's Greetings from the CEO

Other Dec 18, 2025 · 06:00

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Other